820
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected?

Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(10):948-55

, MD PhD, , MD & , MD PhD
Pages 1439-1441 | Published online: 06 May 2010

Bibliography

  • Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-46
  • Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364(9434):613-20
  • Calverley PM, Anderson JA, Celli B, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89
  • Doll R, Peto R, Wheatley K, Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309(6959):901-11
  • Hoogendoorn M, Rutten-Van Molken MP, Hoogenveen RT, A dynamic population model of disease progression in COPD. Eur Respir J 2005;26(2):223-33
  • Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980;93(3):391-8
  • Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;1(8222):681-6
  • Fishman A, Martinez F, Naunheim K, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348(21):2059-73
  • Tashkin D. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med 2010;16(2):97-105
  • Niewoehner DE, Rice K, Cote C, Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143(5):317-26
  • Tashkin DP, Celli B, Senn S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-54
  • Celli B, Decramer M, Kesten S, Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(10):948-55
  • Available from: www.who.int/evidence/bodHealth statistics and health information systems: burden of disease statistics
  • Burchfield CM, Marcus EB, Curb JD, Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995;151(6):1778-85
  • West R, Mcneill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000;55(12):987-99
  • Salpeter SR. Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis 2007;2(1):11-8
  • Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 2006;61(10):854-62

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.